Key terms

About VRTX

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest VRTX news

Yesterday 6:05am ET Vertex Pharmaceuticals sees Q1 capex $20M-$205M by TipRanks Yesterday 2:02am ET Vertex’s High-Stakes Acquisition: Navigating the Uncertainties of the Alpine Deal by TipRanks May 08 10:07pm ET Stifel Nicolaus Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX) by TipRanks May 08 11:11am ET Biotech Alert: Searches spiking for these stocks today by TipRanks May 07 8:56pm ET Vertex Pharmaceuticals price target raised to $477 from $466 at UBS by TipRanks May 07 8:17am ET Oppenheimer Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX) by TipRanks May 07 8:12am ET Truist Financial Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX) by TipRanks May 07 8:08am ET Piper Sandler Releases a Buy Rating on Vertex Pharmaceuticals (VRTX) by TipRanks May 07 8:07am ET Vertex Pharmaceuticals (VRTX) Gets a Hold from RBC Capital by TipRanks May 07 8:03am ET Maintain Position on Vertex Pharmaceuticals: A Hold Rating Despite Strong Quarterly Performance by TipRanks May 07 8:02am ET Buy Rating on Vertex Pharmaceuticals: Promising Kidney Disease Treatments Poised for Market Growth by TipRanks May 07 7:43am ET Vertex Pharmaceuticals (VRTX) Receives a Buy from Barclays by TipRanks May 07 4:25am ET Buy Rating Affirmed for Vertex Pharmaceuticals on Strong Q1 Earnings and Expanding Market Presence by TipRanks May 06 4:03pm ET Vertex Pharmaceuticals affirms FY4 revenue view of $10.55B-$10.75B by TipRanks May 06 4:03pm ET Vertex Pharmaceuticals reports Q1 EPS $4.21, consensus $4.06 by TipRanks May 06 1:55pm ET Notable companies reporting after market close by TipRanks May 06 7:05am ET Options Volatility and Implied Earnings Moves Today, May 06, 2024 by TipRanks May 06 7:01am ET Options Volatility and Implied Earnings Moves This Week, May 06 – May 10, 2024 by TipRanks May 06 6:20am ET Analysts Offer Insights on Healthcare Companies: Owens & Minor (OMI), Vertex Pharmaceuticals (VRTX) and Aldeyra Therapeutics (ALDX) by TipRanks Apr 29 9:41pm ET Analysts Offer Insights on Healthcare Companies: Accolade (ACCD), Vertex Pharmaceuticals (VRTX) and Zimmer Biomet Holdings (ZBH) by TipRanks Apr 26 11:46am ET Vertex announces European Commission approval for KALYDECO by TipRanks Apr 26 11:02am ET Cantor Fitzgerald healthcare analysts hold an analyst/industry conference call by TipRanks Apr 24 7:30am ET Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), HealthStream (HSTM) and Vertex Pharmaceuticals (VRTX) by TipRanks Apr 23 5:33am ET Vertex Pharmaceuticals, TreeFrog Therapeutics announce licensing agreement by TipRanks Apr 22 8:30am ET Vertex Pharmaceuticals (VRTX) Gets a Buy from Piper Sandler by TipRanks Apr 22 1:16am ET Buy Rating on Vertex Pharmaceuticals: Risinger’s Confidence in VX-548’s Billion-Dollar Potential and FDA Progress by TipRanks Apr 19 7:31pm ET CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact by TipRanks Apr 18 6:45pm ET Buy Rating on Vertex Pharmaceuticals Fueled by Promising IgAN Therapy and Strategic Acquisition by TipRanks Apr 18 12:15pm ET Guggenheim Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX) by TipRanks Apr 18 8:30am ET Vertex Pharmaceuticals announces advancements in suzetrigine pain program by TipRanks Apr 15 2:05pm ET Novartis reports results from interim analysis of Phase 3 APPLAUSE-IgAN study by TipRanks

No recent press releases are available for VRTX

VRTX Financials

1-year income & revenue

Key terms

VRTX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

VRTX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Bruce Garelick was found guilty of insider trading
John Minchillo/AP
Investor found guilty in Trump Media insider trading case
People walk toward an entrance to Disneyland in Anaheim, California on April 24, 2023.
Mario Tama/Getty Images/File
Americans are shopping less but they’re still spending on flights, hotels and Disneyland
Scaffolding and construction netting near an apartment building in New York, US, on Wednesday, Oct. 11, 2023. Monthly fees and expenses for inspections, insurance and climate-friendly upgrades are squeezing residents of the city's many co-op and condo buildings. Photographer: Michael Nagle/Bloomberg
Michael Nagle/Bloomberg/Getty Images
For US renters, the chance of owning a home is going from bad to worse
Close-up detail of the Disney+ app icon on an Apple iPhone 12 Pro smartphone screen, on November 11, 2020. (Photo by Phil Barker/Future Publishing via Getty Images)
Phil Barker/Future Publishing/Getty Images
Disney just had its worst day in a year and a half